1 Improving Chronic Care Management David M. Cutler Presented at Alliance for Health Reform Novartis/NIHCM Briefing March 28, 2008.

Slides:



Advertisements
Similar presentations
BY Dr. Khaled Helmy Al Mahmora Chest Hospital BY Dr. Khaled Helmy Al Mahmora Chest Hospital Treatment Of Hypertension In Diabetes.
Advertisements

Impact of Recent Guidelines Recommendations on Hypertension Management Fleetwood Loustalot, Ph.D., F.N.P. Lead, Epidemiology, Surveillance and Health Services.
Economic Impact of a Sedentary Lifestyle. Exercise and Body Composition The health care costs associated with obesity treatment were estimated at $117.
Update on Anti-platelets Gabriel A. Vidal, MD Vascular Neurology Ochsner Medical Center October 14 th, 2009.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.
Early Heart Disease Detection and Prevention Programs.
Valsartan Antihypertensive Long-Term Use Evaluation Results
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Morbidity & Mortality: 2012 Chart Book on Cardiovascular, Lung, and
Type 2 diabetes and high blood pressure How explosive is the cocktail?
Health Disparities in Cardiovascular Disease Paula A. Johnson, MD, MPH Chief, Division of Women’s Health; Executive Director, Connors Center for Women’s.
... a KAISER PERMANENTE Innovation IndiGO: Tailoring Guidelines to Individuals David M Eddy MD PhD Founder and Chief Medical Officer Emeritus Archimedes.
QUALITY USE OF CARDIOVASCULAR MEDICATION Dr Mark Abelson.
December Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation?
Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.
Healthy People 2010 Focus Area 12: Heart Disease and Stroke Progress Review May 21, 2007.
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
HYPERTENSION The Alabama Department of Public Health’s Hypertension Program.
William B. Kannel, MD, FACC Former Director, Framingham Heart Study
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Projecting Future Mortality Using Information on Health Behaviors David M. Cutler, Edward L. Glaeser, and Allison B. Rosen.
M Mohsen Ibrahim, MD CARDIOLOGY DEPARTMENT-CAIRO UNIVERSITY MINIMAL vs OPTIMAL MEDICAL CARE.
Modern Management of Cholesterol in the High-Risk Patient.
 Update on Hypertension Troy L. Randle, DO, FACC, FACOI.
Can pharmacists improve outcomes in hypertensive patients? Sookaneknun P (1), Richards RME (2), Sanguansermsri J(1), Teerasut C (3) : (1)Faculty of Pharmacy,
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
Studying mortality trends: The IMPACT CHD Policy Model
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
Polypill x Aspirin Project Groups 3 and 4
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Pre-ALLHAT Drug Use IMS Health NDTI, Year % of Treated Patients on Medication CCBs Beta Blockers Diuretics ACE Inhibitors.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
2007 Hypertension as a Public Health Risk January, 2007.
Prevalence (%) estimates of diabetes (20-79 years) 2010.
Leading Causes of Death in the US 1. Heart disease: 597,689 2.Cancer: 574,743 3.Chronic lower respiratory diseases: 138,080 4.Stroke (cerebrovascular diseases):
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients Gradman AH, Parisé H, Lefebvre P, Falvey H, Lafeuille MH,
NHS Health Check programme An opportunity to engage 15 million people to live well for longer Louise Cleaver National Programme Support Manager.
Kelsey Vonderheide, PA1.  Heart Failure—a large number of conditions affecting the structure and function of the heart that make it difficult for the.
Global health in the news h/study-shows-spread-of-cigarettes-in- china.html?ref=health&_r=0.
Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
Methods and Statistical analysis. A brief presentation. Markos Kashiouris, M.D.
Powered by Infomedica Infomedica Conference Coverage* of 26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13,
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
From: Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study Ann Intern Med. 2015;163(5):
Hypertension November 2016
Impact and costing of cardiovascular disease treatmentin Kwara State Health Insurance (KSHI) program. University of Ilorin Teaching Hospital (UITH) Amsterdam.
How does teamwork improve value. Dr Nils E
Copyright © 2007 American Medical Association. All rights reserved.
The Anglo Scandinavian Cardiac Outcomes Trial
AIM HIGH Niacin plus Statin to prevent vascular events
Improving Chronic Care Management
Recognizing Your Risk for Cardiovascular Disease
Systolic Blood Pressure Intervention Trial (SPRINT)
Progress and Promise in RAAS Blockade
A. Heart failure: A challenge to the healthcare delivery system
New Opportunities in Medicare
The Hypertension in the Very Elderly Trial (HYVET)
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
American Journal of Kidney Diseases
Hypertension November 2016
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Presentation transcript:

1 Improving Chronic Care Management David M. Cutler Presented at Alliance for Health Reform Novartis/NIHCM Briefing March 28, 2008

2 Hypertension is not well controlled ( )

3 High cholesterol is better treated but still not very successfully

4  What difference does treatment make?  What would be the impact of doing better still?  Analyze the treatment of hypertension Important Questions

5 U.S. age-adjusted death rates from coronary heart disease have fallen by two-thirds since the 1960s Source: Vital Statistics of the United States, NCHS. Deaths per 100,000 Population

6 70% of the improvement in life expectancy over this period was due to cardiovascular disease improvement Source: Calculations from D Cutler, A Rosen, S Vijan. The Value of Medical Spending in the United States, N Engl Med 2006 Aug;355:

7 Approach Predict untreated BP and compare to observed BP for Calculate impact of improvement in BP on risk and number of deaths (2001), heart attack and stroke hospitalizations (2002) See David M. Cutler, Genia Long, Ernst R. Berndt, Jimmy Royer, Andrée- Anne Fournier, Alicia Sasser, and Pierre Cremieux, “The Value Of Antihypertensive Drugs: A Perspective On Medical Innovation”, Health Affairs, January/February 2007; 26(1):

8 Results: antihypertensive therapy reduced average BP by 10 – 13% Definitions: Optimal: SBP =160, DBP>= 100 Men, Women, 60-69

9 Impact on health outcomes Predicted and Observed Deaths, 2001, and Hospital Discharges for Stroke and MI, 2002, Men and Women 86,000 excess premature deaths from CVD avoided (2001) 572,000 hospital discharges for stroke avoided (2002) 261,000 hospital discharges for heart attack avoided (2002) Hospital Discharges for Stroke (2002) Hospital Discharges for Myocardial Infarction (2002) ObservedPredicted Without AntihypertensivesPredicted if All at Guidelines Deaths from Major Cardiovascular Disease (2001)

10 How significant are these estimated reductions relative to some other causes of mortality?  Would have approached all deaths from accidents (98,000, the 5th largest cause of death in )  Would have exceeded all deaths from influenza and pneumonia (64,000, the 7th largest cause of death)  Roughly equivalent to the number of people who are estimated to die of medical errors annually  Would have exceeded all deaths from motor vehicle accidents (42,000 in 2001)

11 There are still significant opportunities for improvement If all untreated patients with Stage I or II hypertension had been treated and all achieved normal blood pressures  An additional 89,000 fewer excess premature deaths from major cardiovascular disease in the U.S. in 2001  An estimated 278,000 fewer US hospital discharges for stroke and 142,000 fewer discharges for myocardial infarctions in 2002 than actually occurred  So far, we have achieved approximately half of the potential health gains

12 Cost benefit: we calculate an approximate benefit- to-cost ratio of 10:1 for men and 6:1 for women  Assume each year of additional life in good health is worth $90,000 a year  Compare discounted lifetime costs for antihypertensive drugs with discounted benefits of additional years of life  Including benefits other than extended life would increase calculated net benefits further: – Reduced hospitalizations for stroke and MI – Impact of antihypertensive drugs on quality of life, work productivity

13 Implications  Under-utilization of effective, cost-efficient therapies continues to be a major public health challenge